NEW YORK(GenomeWeb) – Exact Sciences today priced the public offering of 7 million shares of its common stock at $25.50 per share.

Net proceeds will be used to expand the commercialization of the Cologuard colorectal cancer screening test, which was approved by the US Food and Drug Administration last August. Proceeds will also be used to fund product development and for general corporate and working capital purposes. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.